SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN
Supernus Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Strategic Shifts and Pipeline ...
Supernus Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Strategic Shifts and Pipeline Developments
Supernus Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.002 (vs US$0.31 in 1Q 2023)
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2024 Earnings Call Transcript
Supernus Pharmaceuticals Inc (SUPN) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
Supernus Pharmaceuticals Inc (SUPN) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and Capitalizing on Growth Opportunities
Q1 2024 Supernus Pharmaceuticals Inc Earnings Call Transcript
Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics
Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics
Supernus Pharmaceuticals reports mixed Q1 results; reaffirms FY24 outlook
Supernus Announces First Quarter 2024 Financial Results
M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America
M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree® (Viloxazine XR) in Latin America
Ahead of Supernus (SUPN) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Ahead of Supernus (SUPN) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.